Home › Schizophrenia › Georgia
Schizophrenia clinical trials in Georgia
29 studies for Schizophrenia are looking for participants at sites in Georgia.
Cities in Georgia
Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia
- Atlanta Center for Medical Research, Atlanta
- Local Institution - 0070, Sandy Springs
- Local Institution - 0189, Savannah
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 28, 2026 · NCT07686263A Study of the Feasibility, Safety and Tolerability of Aticaprant as Adjunctive Treatment in Participants With Schizophrenia
- Synexus Clinical Research US Inc, Atlanta
RecruitingPhase 1
Ages 18 to 55 · All sexes · Updated Sep 28, 2026 · NCT07615426Efficacy of NBI-1117568 in Preventing Relapse in Adults With Schizophrenia
- Neurocrine Clinical Site, Atlanta
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT07227818NBI-1117568-SCZ3032: Long-Term Evaluation of NBI-1117568 in Adults With Schizophrenia
- Neurocrine Clinical Site, Atlanta
- Neurocrine Clinical Site, Atlanta
- Neurocrine Clinical Site, Decatur
- and 1 more
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 25, 2026 · NCT07114874Safety and Tolerability Trial of Lumateperone in Pediatric Patients With Schizophrenia, Bipolar Disorder or Autism Spectrum Disorder
- CenExeli Research LLC, Atlanta
- Atlanta Center for Medical Research, Atlanta
- CenExeli Research LLC 1, Savannah
RecruitingPhase 3
Ages 5 to 17 · All sexes · Updated Sep 25, 2026 · NCT06229210A Study of Brenipatide in Adult Participants With Schizophrenia
- Atlanta Center for Medical Research, Atlanta
- Augusta University, Augusta
RecruitingPhase 2
Ages 18 to 55 · All sexes · Updated Sep 22, 2026 · NCT07410507A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
- Atlanta Center for Medical Research, Atlanta
- Salveo Integrative Health - Lawrenceville, Lawrenceville
- Denali Health Atlanta, LLC, Stone Mountain
RecruitingPhase 3
Ages 5 to 17 · All sexes · Updated Sep 22, 2026 · NCT07424404A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
- Neurocrine Clinical Site, Augusta
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 18, 2026 · NCT07105111A Study of LTX-001 In Adult Participants With Acute Exacerbation of Schizophrenia
- CenExel iResearch, LLC, Decatur
RecruitingPhase 1
Ages 18 to 55 · All sexes · Updated Sep 17, 2026 · NCT0773449352-week Open Label Safety-Tolerability Study
- CenExel, Atlanta
- Accelerated Clinical Trial, Snellville
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Sep 9, 2026 · NCT07369154A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolescents (EMERGENT TEEN)
- Atlanta Center for Medical Research, Atlanta
- Salveo Integrative Health - Lawrenceville, Lawrenceville
- Denali Health Atlanta, LLC, Stone Mountain
RecruitingPhase 3
Ages 13 to 17 · All sexes · Updated Sep 4, 2026 · NCT07288567A Study to Evaluate the Safety, Tolerability, and PK of an Injectable Form of KarXT
- Atlanta Center for Medical Research, Atlanta
- CenExel iResearch, LLC, Decatur
RecruitingPhase 1
Ages 18 to 55 · All sexes · Updated Sep 2, 2026 · NCT07061288A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
- Clinical Site, Atlanta
- Clinical Site, Decatur
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Sep 1, 2026 · NCT07459647Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT)
- Emory University., Atlanta
- Local Institution - 0049, Austell
- Local Institution - 0044, Marietta
RecruitingObservational study
Ages 18 and older · All sexes · Updated Aug 19, 2026 · NCT07379827Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder
- Alkermes Investigator Site, Decatur
RecruitingPhase 3
Ages 10 to 17 · All sexes · Updated Aug 14, 2026 · NCT05303064Determining Efficacy and Safety of BXCL501 in Agitation Associated With Pediatric Schizophrenia and Bipolar Disorder
- Bioxcel Clinical Research Site, Decatur
RecruitingPhase 1
Ages 10 to 17 · All sexes · Updated Aug 11, 2026 · NCT05025605Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia
- CenExel iResearch, Decatur
RecruitingPhase 2
Ages 18 to 65 · All sexes · Updated Jul 29, 2026 · NCT07467993Study to Evaluate LB-102 for the Treatment of Adult Patients With Acute Schizophrenia
- Accelerated Clinical Trial, Snellville
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jul 27, 2026 · NCT07363577A Study to Evaluate KYN-5356 in Adults With Cognitive Impairment Associated With Schizophrenia
- Cenexel ACMR, Atlanta
- Cenexel iResearch Atlanta, Decatur
RecruitingPhase 2
Ages 18 to 55 · All sexes · Updated Jun 23, 2026 · NCT07191483Anti-Inflammatory Challenge in Schizophrenia
- Grady Memorial Hospital, Atlanta
- Emory University Hospital, Atlanta
RecruitingPhase 4
Ages 18 to 55 · All sexes · Updated Jun 3, 2026 · NCT05823532CLOZAPINE Response in Biotype-1
- University of Georgia, Athens
RecruitingPhase 4
Ages 18 to 60 · All sexes · Updated May 11, 2026 · NCT04580134Clozapine for the Prevention of Violence in Schizophrenia: a Randomized Clinical Trial
- Augusta University Research Institute, Inc., Augusta
RecruitingPhase 4
Ages 18 to 65 · All sexes · Updated May 4, 2026 · NCT05208190Biomarkers/Biotypes, Course of Early Psychosis and Specialty Services
- University of Georgia, Athens
RecruitingObservational study
Ages 18 to 40 · All sexes · Updated Mar 10, 2026 · NCT06740383NBI-1117568-SCZ3029: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
- Neurocrine Clinical Site, Atlanta
- Neurocrine Clinical Site, Decatur
- Neurocrine Clinical Site, Snellville
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Mar 6, 2026 · NCT06963034Randomized Withdrawal Study in Patients With Schizophrenia
- Vanda Investigational Site, Atlanta
- Vanda Investigational Site, Peachtree Corners
RecruitingPhase 3
Ages 18 to 65 · All sexes · Updated Jan 12, 2026 · NCT06961968Study of ALTO-101 in Patients With Schizophrenia
- Site 5064, Snellville
RecruitingPhase 2
Ages 21 to 55 · All sexes · Updated Dec 26, 2025 · NCT06502964Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
- Vanda Investigational Site, Atlanta
- Vanda Investigational Site, Atlanta
- Vanda Investigational Site, Decatur
RecruitingPhase 4
Ages 12 to 17 · All sexes · Updated Mar 4, 2025 · NCT05648591Cognitive Training for Emotion Regulation in Psychotic Disorders
- University of Georgia, Athens
Recruiting
Ages 18 to 60 · All sexes · Updated Feb 5, 2025 · NCT04414215Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia
- Reviva site, Atlanta
- Reviva site, Decatur
RecruitingPhase 3Healthy volunteers welcome
Ages 18 to 65 · All sexes · Updated Dec 19, 2024 · NCT05184335From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.